Philogen — Innovating targeting
Press releases & media

Press Releases

Announcements issued by Philogen, each linking its official release.

  1. Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

    ·English

    Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for…

  2. Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio

    ·Italiano·English

  3. Comunicazione dell’ammontare complessivo dei diritti di voto

    ·Italiano

  4. Comunicazione variazione capitale sociale Philogen S.p.A.

    ·Italiano

  5. Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.A

    ·English

  6. Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma

    ·English

    NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to…

  7. Philogen announces publication of malignant brain tumor study results in Science Translational Medicine

    ·English

  8. Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity

    ·English

    Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich…

  9. Philogen announces a publication

    ·English

    Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell…

  10. Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancer

    ·English

  11. Philogen received combination pack approval for NidlegyTM

    ·English

  12. Philogen announces Option Exercise by Janssen

    ·English

  13. Keynote lecture of Prof. Dr. Dario Neri

    ·English

    Keynote lecture of Prof. Dr. Dario Neri at Festival of Biologics in Basel on October 15th

  14. Philogen announces capital increase

    ·English

  15. Philogen announces collaboration with Novartis

    ·English

  16. Philogen announces collaboration with Celgene

    ·English

  17. Philogen announces drug discovery collaboration with Johnson & Johnson Innovation

    ·English

  18. Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

    ·English

  19. Philogen Receives Orphan Drug Designation for the Treatment of Melanoma

    ·English

  20. Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation

    ·English

  21. Philogen and the Scripps Research Institute announce research collaboration in the field of DNA-Encoded Chemistry.

    ·English

  22. Philogen announces the authorisation of a clinical trial with PHC-102 for the imaging of renal cell carcinoma.

    ·English

  23. Philogen announces authorization from FDA of a pivotal registration trial in USA for the treatment of resectable melanoma

    ·English

  24. Philogen announces research collaboration with Servier in the field of DNA-encoded chemistry

    ·English

  25. Philogen S.p.A. enters into Multi-Target research agreement

    ·English

    Philogen S.p.A. enters into Multi-Target research agreement with Boehringer Ingelheim in the field of DNA-encoded chemistry.

  26. Philogen S.p.A. announces the publication

    ·English

    Philogen S.p.A. announces the publication in the prestigious Chemistry: A European Journal of a communication entitled: “A specific and covalent JNK-1 ligand…

  27. The European Commission (EC) has granted Orphan Drug Designation to L19TNF

    ·English

    Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

  28. Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech

    ·English

    Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech, Inc., one of the Janssen…

  29. Philogen SpA announced the successful GMP production of  PHC-102 for the imaging of renal cell carcinoma

    ·English

    ​Philogen SpA announced the successful GMP production of PHC-102 for the imaging of renal cell carcinoma and other carbonic anhydrase expressing tumors

  30. Philogen announce expanded research and development agreement with AbbVie

    ·English